Welcome to LookChem.com Sign In|Join Free
The company logo of Chemvon Biotechnology Co. Ltd.

Chemvon Biotechnology Co. Ltd.

Assessed Supplier Enterprise Certification

Assessed
Supplier
17th
years

Chemvon Biotechnology Co. Ltd.

Business Type:Lab/Research institutions

Audited Supplier

Main Products:
Atocalcitol ,Inecalcitol,Alvimopan ,Fosaprepitant, Bimatoprost,Lubiprostone,Tafluprost
Year Established:
2008
Home>>Products>>Vorapaxar Sulfate/ global trader /Reliable quality 705260-08-8 on hot selling

Product Certification&
Enterprise Certification

More Detail

Chemvon Biotechnology Co. Ltd.

Country: China (Mainland)

Business Type:Lab/Research institutions

Mr.peter

Tel: 86-21-58550039;86-21-31268550-8004

Mobile:

Tel: 86-21-58550039;86-21-31268550-8004

Fax: 86-21-50790419

URL: http://www.chemvon.com

Province/state: shanghai

City: shanghai

Street: Suite B-10#, 6999 Chuansha Road, Pudong District, Shanghai 201202, China

MaxCard:


Contact Suppliers

Vorapaxar Sulfate/ global trader /Reliable quality 705260-08-8 on hot selling

CAS NO.705260-08-8

  • Min.Order: 1 Gram
  • Payment Terms: L/C,D/A,D/P,T/T
Contact Supplier

Product Details

Keywords

  • Reliable quality 705260-08-8
  • global trader 705260-08-8
  • 705260-08-8 on hot selling

Quick Details

  • ProName: Vorapaxar Sulfate/ global trader /Reli...
  • CasNo: 705260-08-8
  • Molecular Formula: C29H35FN2O8S
  • Appearance: White powders
  • Application: pharmaceutical raw material
  • DeliveryTime: 3-5 days after confirmation
  • PackAge: According to your demand
  • Port: any port in China
  • ProductionCapacity: 200 Kilogram/Week
  • Purity: 99%
  • Storage: store in a tightly closed container, i...
  • Transportation: by sea or by air
  • LimitNum: 1 Gram

Superiority

Vorapaxar Sulfate global trader Reliable quality 705260-08-8 on hot selling

 

SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis. acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.

Chemvon Biotechnology Co. Ltd is a high-technology pharmaceutical and fine chemical company, which is speciallized in RD, manufacturing and sales of APIs (Active Pharmaceutical Ingredients) and some organic intermediates.
With the experience and specialization in technology of asymmetric synthesis, total synthesis of natural products, organometallic reactions, chromatographic chiral separation, we supply high quality products of APIs, intermediates, speciality chemicals. and our contract services including research manufacture and custom synthesis from laboratory to commercial production are also offered on a confidential basis.
Chemvon puts great emphasis on product quality and service as followed in details:
Custom chemical services:
1. Contract custom manufacturing of intermediates and API's from microgrms up to multi tonnes scale;
2. Contract process research and upscaling studies;
3. Contract research in structure-activity of drug moleculars
Products:
1. Vitamins and steroids;
2. Organic intermediates, heterocyclic compounds including monomers of polymer materials and some building blocks;
3. Chiral synthons with multi-step reactions.
Welcome to you and your visit, let us make progress hand in hand!

Details

Catalogue Number V758200
Chemical Name Vorapaxar Sulfate
Synonyms N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester Sulfate; Sch 530348;
CAS Number 705260-08-8
Alternate CAS # 618385-01-6-free base
Molecular Formula C??H??FN?O?S
Appearance White to Off-White Solid
Melting Point >199ºC (dec.)
Molecular Weight 590.66
Storage Hygroscopic, Refrigerator, under inert atmosphere
Solubility Acetonitrile (Very Slightly, Heated), Methanol (Slightly)
Category Standards; Chiral Molecules; Pharmaceutical/API Drug Impurities/Metabolites;
Applications SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis. It is currently undergoing Phase-III clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.
  Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package